Trial · NCT05059262
Participant flow16
How many started, completed or left each group, period by period.
1 to 16 of 16
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 1: Double Blind (Weeks 1 - 24) | STARTED | Part 1/Part 2: Vimseltinib/Vimseltinib | 83 | |
| Part 1: Double Blind (Weeks 1 - 24) | STARTED | Part 1/Part 2: Placebo/Vimseltinib | 40 | |
| Part 1: Double Blind (Weeks 1 - 24) | Received at Least 1 Dose of Study Drug | Part 1/Part 2: Vimseltinib/Vimseltinib | 83 | |
| Part 1: Double Blind (Weeks 1 - 24) | Received at Least 1 Dose of Study Drug | Part 1/Part 2: Placebo/Vimseltinib | 39 | |
| Part 1: Double Blind (Weeks 1 - 24) | COMPLETED | Part 1/Part 2: Vimseltinib/Vimseltinib | 75 | |
| Part 1: Double Blind (Weeks 1 - 24) | COMPLETED | Part 1/Part 2: Placebo/Vimseltinib | 35 | |
| Part 1: Double Blind (Weeks 1 - 24) | NOT COMPLETED | Part 1/Part 2: Vimseltinib/Vimseltinib | 8 | |
| Part 1: Double Blind (Weeks 1 - 24) | NOT COMPLETED | Part 1/Part 2: Placebo/Vimseltinib | 5 | |
| Part 2: Open Label (Weeks 25 - EoS) | STARTED | Part 1/Part 2: Vimseltinib/Vimseltinib | 74 | |
| Part 2: Open Label (Weeks 25 - EoS) | STARTED | Part 1/Part 2: Placebo/Vimseltinib | 35 | |
| Part 2: Open Label (Weeks 25 - EoS) | Received at Least 1 Dose of Study Drug | Part 1/Part 2: Vimseltinib/Vimseltinib | 72 | |
| Part 2: Open Label (Weeks 25 - EoS) | Received at Least 1 Dose of Study Drug | Part 1/Part 2: Placebo/Vimseltinib | 35 | |
| Part 2: Open Label (Weeks 25 - EoS) | COMPLETED | Part 1/Part 2: Vimseltinib/Vimseltinib | 0 | |
| Part 2: Open Label (Weeks 25 - EoS) | COMPLETED | Part 1/Part 2: Placebo/Vimseltinib | 0 | |
| Part 2: Open Label (Weeks 25 - EoS) | NOT COMPLETED | Part 1/Part 2: Vimseltinib/Vimseltinib | 74 | |
| Part 2: Open Label (Weeks 25 - EoS) | NOT COMPLETED | Part 1/Part 2: Placebo/Vimseltinib | 35 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05059262/flow